**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 54-year-old woman developed intestinal perforation during off-label treatment with methylprednisolone and tocilizumab for SARS-CoV-2 \[*routes not stated; not all dosages stated*\].

The woman, with a significant history of dyslipidemia, high blood pressure, obesity and epilepsy, presented to an emergency department with myalgia, coughing and costal pain. Subsequent blood tests showed increased ferritin, C-reactive protein and lactate dehydrogenase with lymphopenia. Chest x-ray revealed bilateral pulmonary condensation compatible with viral pneumonia. Based on positive polymerase chain reaction (PCR), she was diagnosed with SARS-CoV-2. She was hospitalised and started receiving off-label treatment with hydroxychloroquine and lopinavir/ritonavir. However, on hospital day 2, she exhibited sudden worsening of respiratory condition. She was transferred to an ICU due to her worsening condition and increased need of oxygen therapy. Following intubation, she received methylprednisolone boluses and a single dose of tocilizumab 600mg. She had a favorable progression with this treatment. However, after 15 days of admission, she developed fever. On the next day, she exhibited a sudden worsening with haemodynamic instability and anemization. Subsequent CT-scan showed an active bleeding in the caecum with pneumoperitoneum, compatible with an intestinal perforation.

The woman therefore underwent an urgent midline laparotomy and moderate hemoperitoneum was evacuated. Following lavage of the cavity, a 3cm perforation was noted in the right colon, without associated ischaemia. Therefore, a right colectomy with terminal ileostomy was performed. However, within 24 hours of surgery, she died due to multi-organ failure.
